- US12616700utility2026Therapeutic Regimen0 cites3.0 ★
- US12617774utility2026Substituted Indole Compounds and Methods of Use Thereof0 cites3.0 ★
- US12605451utility2026Targeted Plasma Protein Degradation0 cites
- US12605506utility2026Automatic Drug Delivery Device0 cites
- US12600728utility2026Interleukin-17 Inhibitors0 cites
- US12600769utility2026Stable and Soluble Antibodies Inhibiting VEGF0 cites
- US12599664utility2026Pharmaceutical Products and Stable Liquid Compositions of IL-17 Antibodies0 cites
- US12594332utility2026Methods of Treating Psoriasis with Secukinumab0 cites
- US12594333utility2026Methods of Treating Inflammatory Arthritis Using IL-17 Antagonists0 cites
- US12594331utility2026Methods of Treating Psoriasis with Secukinumab0 cites
- US12595305utility2026TREM2 Stabilizing Antibodies0 cites
- US12595306utility2026TREM2 Stabilizing Antibodies0 cites
- US12570625utility20263-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses Thereof0 cites
- US12570733utility2026Anti-betacellulin Antibodies, Fragments Thereof, and Multi-specific Binding Molecules0 cites
- US12570754utility2026Regimens and Methods of Treating Multiple Sclerosis Using Ofatumumab0 cites
- US12551554utility2026Methods of Treating Chronic Inflammatory Disease with Secukinumab0 cites
- US12544374utility2026Aza-quinoline Compounds and Uses Thereof0 cites
- US12544379utility2026Combination Therapy Using Ribociclib and Fulvestrant for the Treatment of HR+ Breast Cancer0 cites
- US12544380utility2026Combination Therapy Using Ribociclib and an Aromatase Inhibitor for the Treatment of HR+ Breast Cancer0 cites
- US12544438utility2026Pharmaceutical Products and Stable Liquid Compositions of IL-17 Antibodies0 cites
Page 1 of 12Next →